Genetic retargeting of E3 ligases to enhance CAR T cell therapy-Reference-Cited by-同舟云学术

Genetic retargeting of E3 ligases to enhance CAR T cell therapy

Published:2023-11 Issue: Volume: Page:
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Lane Isabel C.,Kembuan Gabriele,Carreiro Jeannie,Kann Michael C.,Lin William,Bouffard Amanda A.,Kreuzer Johannes,Morris Robert,Schneider Emily M.,Kim Joanna Y.,Zou Charles,Salas-Benito Diego,Gasser Jessica A.,Leick Mark B.,Słabicki Mikołaj,Haas Wilhelm,Maus Marcela V.,Jan Max^ORCID

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference53 articles.

1. Tumor immunology CRISPR screening: present, past, and future;Dong;Trends Cancer,2022

2. CRISPR-Based Tools in Immunity;Simeonov;Annu. Rev. Immunol.,2019

3. CRISPR-engineered T cells in patients with refractory cancer;Stadtmauer;Science,2020

4. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells;Fraietta;Nature,2018

5. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity;Prinzing;Sci. Transl. Med.,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets;Experimental Hematology & Oncology;2024-08-30

2. CD28 co-stimulation: novel insights and applications in cancer immunotherapy;Nature Reviews Immunology;2024-07-25

3. Degron-Based bioPROTACs for Controlling Signaling in CAR T Cells;ACS Synthetic Biology;2024-07-11

4. Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy;Cell Chemical Biology;2024-02